4.4 Article

Performance of the Assessment of Quality of Life Measure in People With Hip and Knee Joint Disease and Implications for Research and Clinical Use

期刊

ARTHRITIS CARE & RESEARCH
卷 66, 期 3, 页码 481-488

出版社

WILEY
DOI: 10.1002/acr.22129

关键词

-

资金

  1. Physiotherapy Research Foundation
  2. Pacific Industries Thermoskin Research Grant [T09-THE003]
  3. National Health and Medical Research Council of Australia Public Health (Australian) Early Career Fellowship [520004]
  4. Melbourne EpiCentre
  5. Centre for Research Excellence in Translational Neuroscience (Royal Melbourne Hospital)
  6. Centre for Research Excellence in Translational Neuroscience (The University of Melbourne)
  7. AbbVie
  8. Amgen
  9. AstraZeneca
  10. Bristol-Myers Squibb
  11. Pfizer
  12. Sanofi

向作者/读者索取更多资源

ObjectiveTo comprehensively evaluate the performance of the Assessment of Quality of Life (AQoL) instrument for measuring health-related quality of life (HRQOL) in people with hip and knee joint disease (arthritis or osteoarthritis). MethodsData from 237 individuals were available for analysis from a national cross-sectional, population-based study of hip and knee joint disease in Australia. AQoL-4D data were evaluated using Rasch analysis. A range of measurement properties was explored, including model and item fit, threshold ordering, differential item functioning, and targeting. ResultsGood overall fit of the AQoL with the Rasch model was demonstrated across a range of tests, supporting internal validity. Only 1 item (relating to hearing) showed evidence of misfit. Most AQoL items showed logical sequencing of response option categories, with threshold disordering evident for only 2 of the 12 items (items 4 and 9). Minor issues with potential clinical and research implications include limited options for reporting pain and some evidence of measurement bias between demographic subgroups (including age and sex). Participants' HRQOL was generally better than that represented by the AQoL items (mean SD for person abilities -2.15 +/- 1.39, mean +/- SD for item difficulties 0.00 +/- 0.67), indicating ceiling effects that could impact the instrument's ability to detect HRQOL improvement in population-based studies. ConclusionThe AQoL is a competent tool for assessing HRQOL in people with hip and knee joint disease, although researchers and clinicians should consider the caveats identified when selecting appropriate HRQOL measures for future outcome assessment involving this patient group.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据